Our medical team has made new progress in the treatment of blood tumor cells.

According to Xinhua News Agency, it was learned from Tongji Medical College of Huazhong University of Science and Technology affiliated Union Hospital that the hospital's hematology team recently achieved clinical success in treating multiple myeloma with in vivo chimeric antigen receptor T cell therapy, making new progress in the field of blood tumor cell therapy. This new therapy adopts the in vivo preparation mode of CAR-T, which can simplify operation, reduce costs, and is expected to greatly improve the accessibility of cell therapy compared to the traditional ex vivo preparation of CAR-T therapy. CAR-T is a novel immunotherapy in which T lymphocytes are isolated from the patient, and then through genetic engineering technology, the T cells are endowed with the ability to recognize specific tumor cells and selectively kill them. Currently, this therapy is mainly used for the treatment of certain hematologic malignancies.